Compare IPCA Labs with Fresenius Kabi Onco. - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

IPCA LABS vs FRESENIUS KABI ONCO. - Comparison Results

IPCA LABS     Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

FRESENIUS KABI ONCO. 
   Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    IPCA LABS FRESENIUS KABI ONCO. IPCA LABS/
FRESENIUS KABI ONCO.
 
P/E (TTM) x 23.1 22.1 104.2% View Chart
P/BV x 4.5 3.1 143.7% View Chart
Dividend Yield % 0.1 0.0 -  

Financials

 IPCA LABS   FRESENIUS KABI ONCO.
EQUITY SHARE DATA
    IPCA LABS
Mar-18
FRESENIUS KABI ONCO.
Mar-13
IPCA LABS/
FRESENIUS KABI ONCO.
5-Yr Chart
Click to enlarge
High Rs695176 395.1%   
Low Rs40079 509.6%   
Sales per share (Unadj.) Rs260.237.7 690.4%  
Earnings per share (Unadj.) Rs19.05.1 372.5%  
Cash flow per share (Unadj.) Rs33.16.7 491.7%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs213.042.5 500.7%  
Shares outstanding (eoy) m126.20158.23 79.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.13.4 62.3%   
Avg P/E ratio x28.925.0 115.6%  
P/CF ratio (eoy) x16.618.9 87.5%  
Price / Book Value ratio x2.63.0 86.0%  
Dividend payout %5.30-   
Avg Mkt Cap Rs m69,12020,135 343.3%   
No. of employees `00013.31.2 1,150.5%   
Total wages/salary Rs m7,359703 1,046.5%   
Avg. sales/employee Rs Th2,477.45,176.2 47.9%   
Avg. wages/employee Rs Th555.2610.4 91.0%   
Avg. net profit/employee Rs Th180.6699.6 25.8%   
INCOME DATA
Net Sales Rs m32,8365,963 550.7%  
Other income Rs m41818 2,322.2%   
Total revenues Rs m33,2545,981 556.0%   
Gross profit Rs m4,5051,430 315.0%  
Depreciation Rs m1,777258 689.1%   
Interest Rs m240-26 -923.8%   
Profit before tax Rs m2,9051,216 238.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-68 0.0%   
Tax Rs m511342 149.4%   
Profit after tax Rs m2,394806 297.1%  
Gross profit margin %13.724.0 57.2%  
Effective tax rate %17.628.1 62.5%   
Net profit margin %7.313.5 54.0%  
BALANCE SHEET DATA
Current assets Rs m19,4555,102 381.3%   
Current liabilities Rs m10,0762,385 422.4%   
Net working cap to sales %28.645.6 62.7%  
Current ratio x1.92.1 90.3%  
Inventory Days Days98150 65.2%  
Debtors Days Days67113 59.1%  
Net fixed assets Rs m20,2605,148 393.5%   
Share capital Rs m252158 159.5%   
"Free" reserves Rs m26,6336,556 406.3%   
Net worth Rs m26,8866,732 399.4%   
Long term debt Rs m2,340952 245.8%   
Total assets Rs m41,17310,388 396.4%  
Interest coverage x13.1-45.8 -28.6%   
Debt to equity ratio x0.10.1 61.5%  
Sales to assets ratio x0.80.6 138.9%   
Return on assets %6.47.5 85.2%  
Return on equity %8.912.0 74.4%  
Return on capital %10.814.6 73.7%  
Exports to sales %47.674.5 64.0%   
Imports to sales %14.924.8 60.0%   
Exports (fob) Rs m15,6424,441 352.3%   
Imports (cif) Rs m4,8841,477 330.6%   
Fx inflow Rs m15,6425,298 295.3%   
Fx outflow Rs m4,8841,772 275.6%   
Net fx Rs m10,7593,525 305.2%   
CASH FLOW
From Operations Rs m3,4111,274 267.7%  
From Investments Rs m-1,354-1,204 112.4%  
From Financial Activity Rs m-1,304-196 665.0%  
Net Cashflow Rs m753-126 -596.4%  

Share Holding

Indian Promoters % 45.9 0.0 -  
Foreign collaborators % 0.0 81.0 -  
Indian inst/Mut Fund % 11.4 0.3 3,800.0%  
FIIs % 25.3 9.6 263.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.4 9.1 191.2%  
Shareholders   36,892 42,599 86.6%  
Pledged promoter(s) holding % 2.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare IPCA LABS With:   NATCO PHARMA  PLETHICO PHARMA  GLENMARK PHARMA  TORRENT PHARMA  PANACEA BIOTECH  

Compare IPCA LABS With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex's Journey From 640 Points Down to 2,000 Points Up(Podcast)

What a week it was! While crude oil prices dragged the Indian stock markets lower, finance minister Nirmala Sitharaman's boosters sent markets soaring and how!

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY19); Net Profit Up 51.7% (Quarterly Result Update)

Feb 14, 2019 | Updated on Feb 14, 2019

For the quarter ended December 2018, IPCA LABS has posted a net profit of Rs 2 bn (up 51.7% YoY). Sales on the other hand came in at Rs 9 bn (up 10.3% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY19); Net Profit Up 24.1% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, IPCA LABS has posted a net profit of Rs 1 bn (up 24.1% YoY). Sales on the other hand came in at Rs 10 bn (up 15.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY19); Net Profit Down 423.6% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, IPCA LABS has posted a net profit of Rs 655 m (down 423.6% YoY). Sales on the other hand came in at Rs 9 bn (up 19.8% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Rare Opportunity to Buy the Top 5 Stocks in the Market(The 5 Minute Wrapup)

Sep 16, 2019

The stock market today is throwing up a great opportunity to pile on quality stocks.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

The 5 Best Trading Opportunities I've Spotted(Profit Hunter)

Sep 13, 2019

These 10 auto stocks should be in your watchlist for the next 32 months. Paste them on your workstation NOW.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

IPCA LABS SHARE PRICE


Sep 20, 2019 (Close)

TRACK IPCA LABS

  • Track your investment in IPCA LABS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE IPCA LABS WITH

MARKET STATS